Apogee Therapeutics (APGE) Interest Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Interest Expenses data on file, last reported at $268.2 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 681450.39% year-over-year to $268.2 million in Q1 2026; TTM through Mar 2026 was $268.2 million, a 681450.39% increase from a year earlier, with the FY2025 full-year figure at $216.2 million, up 184.12% from the prior year.
• Interest Expenses for Q1 2026 stood at $268.2 million, up from $216.2 million in the prior quarter.
• Over the last five years, Interest Expenses for APGE reached as high as $268.2 million in Q1 2026 and fell as low as $39345.0 in Q1 2025.
• Historically, Interest Expenses has averaged $66.8 million across 5 years, with a median of $37.1 million in 2023.
• Across the five-year window, Interest Expenses slumped 99.97% in 2025 and surged 681450.39% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $6.7 million in 2022, then soared by 351.56% to $30.2 million in 2023, then soared by 103.81% to $61.5 million in 2024, then jumped by 251.46% to $216.2 million in 2025, then rose by 24.05% to $268.2 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $268.2 million in Q1 2026, $216.2 million in Q4 2025, and $43.9 million in Q3 2025.